Omeros (OMER) FCF Margin (2010 - 2026)

Omeros (OMER) reported FCF Margin of 146.63% for Q1 2026, up 23.92% sequentially from 192.72% in Q2 2022.

Omeros (OMER) FCF Margin (2010 - 2026) Analysis & Trends

Omeros (OMER) has 14 years of FCF Margin data on file, last reported at 146.63% in Q1 2026.

For the quarter ending Q1 2026, FCF Margin changed N/A year-over-year to 146.63%; the trailing twelve-month figure through Mar 2026 stood at 351.17% (down 57893.0% YoY), and the FY2020 full-year result was 135.98%, down 8195.0% from the prior year.
FCF Margin rose to 146.63% in Q1 2026, from 192.72% in the prior quarter.
In the past five years, FCF Margin ranged from a high of 146.63% in Q1 2026 to a low of 217.17% in Q1 2022.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	10.45%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	43.35%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	23.53%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Omeros	739.31 Mn	739.31 Mn	9.31 Mn	-146.63%

Historic Data

Download Data

Date	Value
Mar 31, 2026	-146.63%
Jun 30, 2022	-192.72%
Mar 31, 2022	-217.17%
Dec 31, 2021	22.89%
Sep 30, 2021	-79.20%
Jun 30, 2021	-96.03%
Mar 31, 2021	-191.19%
Dec 31, 2020	-173.13%
Sep 30, 2020	-134.08%
Jun 30, 2020	-278.94%
Mar 31, 2020	-39.12%
Dec 31, 2019	-68.92%
Sep 30, 2019	-25.32%
Jun 30, 2019	-62.37%
Mar 31, 2019	-60.29%
Dec 31, 2018	-112.41%
Sep 30, 2018	-802.13%
Jun 30, 2018	-1,879.94%
Mar 31, 2018	-722.86%
Dec 31, 2017	-30.32%